Efficacy Study of Intra-hepatic Administration of Therasphere® in Association With Intravenous Chemotherapy to Treat Cholangiocarcinoma


The purpose of this study is to assess efficacy and tolerance of intra-hepatic administration of Yttrium 90-labelled microsphere (Theraspheres®, Nordion) in association with intravenous chemotherapy with Gemcitabin and Cisplatin for the treatment of intra-hepatic cholangiocarcinoma.

Full Title of Study: “An Open-label, Multicenter, Phase II Trial, to Evaluate the Efficacy of Intra-hepatic Administration of Yttrium 90-labelled Microspheres (Therasphere®, Nordion) in Association With Intravenous Chemotherapy With Gemcitabine and Cisplatin for the Treatment of Intra-hepatic Cholangiocarcinoma, First Line.”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: December 2016


  • Radiation: Therasphere® in association with Gemcitabine and Cisplatin
    • Therasphere® is a radioelement

Arms, Groups and Cohorts

  • Experimental: Therasphere®
    • Therasphere® in association with Gemcitabine and Cisplatin

Clinical Trial Outcome Measures

Primary Measures

  • Radiological response rate to the treatment with the association of chemotherapy and radioembolization
    • Time Frame: 3 months after radioembolization
    • Evaluation according RECIST 1.1 criteria. Rate will be reassessed every 8 weeks

Secondary Measures

  • Tolerance of intra-hepatic administration of Yttrium 90-labelled microspheres in association with intravenous chemotherapy with Gemcitabine and Cisplatin assessed according NCI/CTC AE version 4.
    • Time Frame: Up to 24 months
    • Grade 3-4 toxicity appearance.Time between 1st treatment administration and date of 1st appearance of a grade 3-4 toxicity or date of last toxicities assessment in case no grade 3-4 toxicity
  • Tumor markers changes (CA19.9, CEA and AFP)
    • Time Frame: Up to 24 months
    • Markers will be analysed every 8 weeks during treatment period and if applicable every 12 weeks after surgery
  • Radiological response rate by the CHOI criteria
    • Time Frame: Up to 24 months
    • every 8 weeks and every 12 weeks after surgery if applicable
  • Change in metabolic activity measured by TEP
    • Time Frame: Change from baseline in metabolic activity 15 and 24 weeks after last treatment by microspheres
  • Changes of liver volume
    • Time Frame: Up to 24 months
    • Every 8 weeks during treatment and every 12 weeks after surgery if applicable
  • Tumoral and non-tumoral dosimetric assessment of the liver
    • Time Frame: Up to 6 months
    • Data obtained from SPECT/CT performed at each hepatic scintigraphy

Participating in This Clinical Trial

Inclusion Criteria

1. Histologically confirmed intra-hepatic cholangiocarcinoma.

2. Measurable target of at least 2 cm diameter.

3. Healthy liver or cirrhosis CHILD < B8.

4. WHO-PS: 0-1.

5. Age ≥ 18 years.

6. Non-Metastatic disease in extra-hepatic (are permitted: local lymph nodes < 3 cm, less than 5 lung nodes < 11 mm).

7. Creatinine clearance (calculated with Cockcroft and Gault formula) ≥ 55 ml/min, polymorphonuclear neutrophils ≥ 1500 G/L, platelets ≥ 80 G/L, prothrombin ≥ 40% (INR ≤ 2.3), serum albumin ≥ 28 g/l, serum bilirubin ≤ 3 x LSN.

8. Pregnancy test: negative for women of childbearing potential.

9. Reliable contraception for a childbearing couple, men and woman must have an reliable contraception during the treatment and until 6 months following the end of the treatment by chemotherapy

10. Signed informed consent form.

11. Patient with national health insurance.

Exclusion Criteria

1. Pancreas cancer or duodenum cancer invading the bile duct or ampullary cancer. Cholangiocarcinoma of the bile ducts: hilar, main duct, gallbladder.

2. Extra-hepatic metastasis (including local lymph nodes measuring > 30 mm).

3. Primary sclerosing cholangitis.

4. History of chemoembolization or radioembolization.

5. Cirrhose CHILD > B7

6. Portal vein trunk tumoral thrombosis

7. History of hepato-biliary neo adjuvant or palliative chemotherapy and/or radiotherapy.

8. Contra indication of Gemcitabine and/or Cisplatin.

9. Other invasive active cancer, excepting in situ cervical cancer and basocellular or spino cellular skin cancer treated adequately. Any history of cancer not considered as completely cured for at least one year.

10. Technical failure of the diagnostic arteriography.

11. Extra hepatic uptake on the pre-therapeutic scintigraphy not manageable with an arteriography.

12. Dosimetry study predicting lung exposure > 30 Gy.

13. Any unstable medical history (diabetes, hypertension …).

14. History of organ transplant.

15. Symptomatic grade 1 angina pectoris or grade ≥ 2 angina pectoris.

16. An evolutive neuropathy.

17. Patient who already has been involved in a clinical trial with drug intake, whether this drug was experimental or not, within 30 days before.

18. Pregnant patient or patient with breastfeeding.

19. Patient under administrative supervision.

20. Regular follow-up impossible for various reasons (psychological, familial, economical, and social).

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Center Eugene Marquis
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Eveline Boucher, MD, Principal Investigator, Centre Eugene Marquis

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.